Indaptus Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Indaptus Therapeutics generated cash of -$13,405,315, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $3,735,253.
Cash Flow
| 2015 | -7.92M | -6.39M | 31.93M |
|---|---|---|---|
| 2017 | -22.13M | -4.74M | 63.70M |
| 2019 | -29.04M | -3.21M | 2.36M |
| 2020 | -3.32M | 0 | 1.16M |
| 2021 | -11.29M | 447.74K | 48.33M |
| 2022 | -13.07M | -16.42M | 0 |
| 2023 | -13.40M | 17.14M | 0 |
INDP Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.62M | 39.13M | 1.63M | 3.79M | 39.24M | 16.43M | 6.15M |
Operating activities | |||||||
Net income | -15.42M | -14.32M | -7.71M | -3.58M | -47.59M | -28.90M | -7.17M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.28K | 1.78K | 1.40K | 852 | 854K | 829K | 745.90K |
Stock-based compensation expense | 2.96M | 2.95M | 1.51M | 139.96K | 124.36K | 0 | 0 |
| Deferred income tax benefit | 2.96M | 2.95M | 1.51M | 139.96K | 124.36K | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 3.38M | -747K | 1.25M | -2.08M |
Inventories | 0 | 0 | 0 | -3.38M | 0 | 0 | 0 |
Accounts payable | -680.52K | -1.15M | -4.23M | 113.9K | 679K | 3.83M | 0 |
Cash generated by operating activities | -13.40M | -13.07M | -11.29M | -3.32M | -29.04M | -22.13M | -7.92M |
Investing activities | |||||||
Purchases Of Investments | -6.85M | -29.59M | 0 | 0 | 0 | 0 | -4.99M |
Investments In Property Plant And Equipment | 0 | -172.55K | -3.85K | 0 | -921K | -5.00M | -1.39M |
Acquisitions Net | 0 | 172.55K | 451.6K | 0 | 0 | 7K | 0 |
Cash generated by investing activities | 17.14M | -16.42M | 447.74K | 0 | -3.21M | -4.74M | -6.39M |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 5M | 1.16M | 2.36M | 63.70M | 31.93M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 0 | 0 | 48.33M | 1.16M | 2.36M | 63.70M | 31.93M |
Net Change In Cash | 3.73M | -29.50M | 37.49M | -2.16M | -29.95M | 36.95M | 17.62M |
Cash at end of period | 13.36M | 9.62M | 39.13M | 1.63M | 9.29M | 53.39M | 23.77M |
| Data source | Data source | Data source |